Table 2d. Prevalence of Other Metabolic Late Effects in At-Risk Populations Following Exposure-Based Screening.

				Diagnosis before SJLIFE			Diagnosis related to SJLIFE			Diagnosis after SJLIFE			Overall Prevalence
Potential Late Effect	Screening test	Exposure Status	Number at riska	N	(%)	95% CI	N	(%)	95% CI	N	(%)	95% CI	N	(%)	95% CI
Hematology
Abnormal blood counts	Complete blood count with differential	Alkylating agents Anthracyclines Epipodophyllotoxins	1375	16	(1.2)	[0.7-1.9]	20	(1.5)	[0.9-2.2]	4	(0.3)	[0.1-0.7]	40b	(3.0)	[2.1-3.9]
Hepatic
Hepatopathy	Alanine aminotransferas e (ALT), aspartate aminotransferas e (AST), bilirubin	Mercaptopurine/Thio guanine Radiation to liver (dose >= 30 Gy)	920	34	(3.7)	[2.6-5.1]	65	(7.1)	[5.5-8.9]	20	(2.2)	[1.3-3.3]	119c	(13.0)	[10.8-15.3]
Skeletal
Osteoporosis	Dual X-ray Absorptiometry	Methotrexate Corticosteroids Radiation to hypothalamic- pituitary	1142	23	(2.0)	[1.3-3.0]	87	(7.6)	[6.1-9.3]	0	(0.0)		110d	(9.6)	[8.0-11.5]
Urinary tract
Kidney dysfunction	Urinalysis BUN, Creatinine, Na, K, Cl, CO2, Ca, Mg, PO4	Ifosfamide Cisplatin/Carboplatin Methotrexate Radiation to kidney Nephrectomy	1410	35	(2.5)	[1.7-3.4]	33	(2.3)	[1.6-3.3]	3	(0.2)	[0.0-0.6]	71e	(5.0)	[4.0-6.3]

^aAt risk by treatment exposure as defined in the COG Guidelines, see supplemental Table 1 for detailed exposures and potential late effects evaluated by risk-based screening.

^bNone of the cases were CTCAE v.4 Grade 3-4

^c20.0% were CTCAE v.4 Grade 3-4

^dAll cases were CTCAE v.4 Grade 3-4

^e15.2% were CTCAE v.4 Grade 3-4

CTCAE v.4 percentages includes only those who fulfill criteria for “at risk” as defined by COG Guidelines.